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Inflammation, altered immune cell phenotype, and functions are key features shared by diverse chronic diseases, including
cardiovascular, neurodegenerative diseases, diabetes, metabolic syndrome, and cancer. Natural killer cells are innate lymphoid
cells primarily involved in the immune system response to non-self -components but their plasticity is largely influenced by the
pathological microenvironment. Altered NK phenotype and function have been reported in several pathological conditions,
basically related to impaired or enhanced toxicity. Here we reviewed and discussed the role of NKs in selected, different, and
“distant” chronic diseases, cancer, diabetes, periodontitis, and atherosclerosis, placing NK cells as crucial orchestrator of these
pathologic conditions.
1. Introduction
Inflammation is now considered a crucial hallmark of chronic
disorders, including cardiovascular [1], neurodegenerative
diseases [2–4], diabetes [5, 6], metabolic syndrome [7, 8],
and cancer [9–11]. Inflammation acts as a relevant orches-
trator in their insurgence, development, and progression
[1, 2, 6, 10]. Inflammatory cells, which comprise cells from
innate ad adaptive immunity, are characterized by different
phenotype and functions, which involve direct (by con-
tact) or distant (by soluble factors) interaction with their
target cells [12–14]. Immune cells, form either innate or
adaptive immunity, given their cellular plasticity, have been
reported to acquire an altered phenotype upon different
stimuli. This has been described for diverse immune cell
type, including macrophages (M), neutrophils (N), myeloid-
derive-suppressor cells (MDSC), dendritic cells (DC), natural
killer (NK) cells, and T cells [12–14]. Immune cell altered
functions include attenuation of targeting/killing activities,
tolerogenic/immunosuppressive behaviour, and the acquisi-
tion of proangiogenic functions. These alterations, occurring
at both tissue levels and systemically, are finely tuned by
the (chronic) pathological environment. Here, we focused on
NKs as key orchestrator in inflammatory chronic diseases,
such cancer, type 1 diabetes, periodontitis, and atherosclero-
sis. The aim was to discuss how such very different patholo-
gies, with diverse aetiology and photogenic mechanisms,
share a common and relevant hallmark, such inflammation,
dissecting whether NK cells act as crucial orchestrators in the
induction and progression of the conditions selected.
NKs are innate lymphoid cells, primarily involved in
the host defence against infection and in the process of
tumour immunosurveillance. A part from their crucial role
in those processes, NK cells are involved in the graft-versus-
host disease, the regulation of haematopoiesis, and exert
regulatory effects on the adaptive immune cell counterpart
[15]. Virus infected and tumour transforming cells share
the feature of low/null expression of the MHC-I molecule,
representing one of the mechanisms through which NK cells
are able to recognize target/non-self -cells. Nevertheless, this
mechanism alone does not trigger cytotoxicity, unless it is
combined with the altered expression of other molecules
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Figure 1: Different human NK subsets. Three different NK subsets have been characterized on the basis of distinctive surface antigen
expression and described as (a) CD56dimCD16+ that represents the conventional cytotoxic NKs, characterized by the high release of perforin
and granzymes; (b) CD56brightCD16− that are able to release a large amount of cytokines; (c) CD56superbrightCD16− that are able to produce
proangiogenic factors, including VEGF, IL-8, and SDF-1 and are characterized by the expression of specific surface markers as CD9 and
CD49a.
on the target cell surface, acting as activatory ligands. NK
cells are equipped with surface receptors that trigger cell
activation (immunoreceptor tyrosine-based activationmotifs
(ITAM)) or inhibition (immune tyrosine-based inhibitory
motifs (ITIM)) [16]. NK cells also directly contribute to
adaptive immune responses, interacting with DCs and by
triggering T cell responses. Induction of DC maturation to
produce TNF-𝛼 and IL-12 and upregulation of costimulatory
ligands are triggered by NK cells [17]. Moreover, NK cells
proliferate and acquire cytotoxic activity and the capacity
to produce IFN-𝛾 through the interaction with DCs [18].
Apart from activation of other cells of innate immunity,
NK cells also enhance induction of CD8+ T cell responses
that is influenced by NK-released IFN-𝛾, which promotes
antigen processing and presentation to T cells and T helper
type 1 (Th1) cell polarization [19]. Two major circulating
human NK cell subsets have been characterized based on
the expression of surface antigens: CD56, an isoform of the
human neural cell adhesion molecule, and CD16, the low-
affinity Fc receptor necessary for the antibody-dependent
cellular cytotoxicity (ADCC). Peripheral NK cells are pre-
dominantly CD56dimCD16+ cytotoxic NK cells acting mainly
through the release of perforin, a membrane pore-forming
toxin, and granzyme which activates the apoptotic cascade
on target cells. However, approximately 5% of circulating
NK cells show a CD56brightCD16− phenotype. These cells
can produce high levels of some cytokines. Upon activation,
CD56brightCD16− NK cells release IFN-𝛾 and TNF-𝛼, and
they kill target cells more efficiently [20].Within the develop-
ing decidua, a third NK subset is found, the decidual NK cell
(dNK). dNK cells display a CD56superbrightCD16− phenotype
[21] and are closely linked with vascularization of the decidua
in both humans and mice. dNK cells physiologically produce
VEGF, PlGF, and IL-8, are poorly cytotoxic, and are associated
with the induction of CD4+ T regulatory (Treg) cells [22, 23]
(Figure 1).
2. Natural Killer Cells and Cancer
Strong evidences suggest that the presence of inflammatory
cells within the tumour microenvironment (TME) plays a
crucial role in the development and/or progression of human
cancers [10, 12, 24–27]. Among the host-dependent biological
features of the tumour hallmarks, defined by Hanahan and
Weinberg [28], there are “evading immune destruction” and
“tumour-promoting inflammation,” which together with the
immune orchestration of angiogenesis point out the key role
of the immune system in neoplastic diseases [9, 10, 12, 24].
Alterations in NK cell activity have been described
in different type of cancer and are associated with the
induction of a tolerogenic and less/poor cytotoxic func-
tions with decreased expression of the activatory receptor
NKG2D, altered degranulation, and release of perforin and
granzyme. Recently, Bruno et al. identified a new NK cell
subset in tissue and peripheral blood of non-small-cell
lung cancer (NSCLC) patients, termed, respectively, tumour
infiltrating (TINKs) and tumour associated (TANKs) NKs,
which are able to promote angiogenesis [29, 30]. NSCLC
TINK/TANKs are characterized by a decidual like pheno-
type CD56brightCD16−VEGFhighPlGFhighIL-8+IFN-𝛾low, able
to promote endothelial cell migration and induction of
capillary-like structures [29, 30].
Several TME released components, including TGF-𝛽,
hypoxia, and adenosine, mostly shared with the decidual
tissues, are implicated in NK cell response against tumours
[31] (Figure 2).
TGF-𝛽 is one of the numerous TME factors involved
in the induction of immune cell polarization [32] and is
expressed at high levels both in the tumour microenvi-
ronment and in the decidua [29]. During carcinogenesis,
TGF-𝛽 acts as a tumour suppressor, by inhibiting tumour
cell replication and favouring apoptosis [33, 34], while at
later stages of tumour progression it exerts protumourigenic
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Figure 2: Soluble factors within the tumour microenvironment shaping NK cell functions. Several molecules and soluble factors within the
tumourmicroenvironment, including TGF-𝛽, hypoxia, adenosine, acidic of the environment, and tumour exosomes (TEXOs), can inhibit NK
response against tumours either by interfering with NK cell direct/cytokinemediated tumour cell lysis or by supporting tumour angiogenesis.
effects that include tumour survival, induction of epithelial-
mesenchymal transition (EMT), enhanced tumour invasion,
and immunosuppressive and proangiogenic activities [32–
34]. TGF-𝛽 has been found to polarize the CD56dimCD16+
peripheral NK cells towards a decidual like phenotype,
defined asCD56brightCD16− andKIR+ CD9+ CD49a+ [29, 35–
37]. TGF-𝛽 has been shown to inhibit CD16mediated human
NK cell IFN-𝛾 production and ADCC though SMAD3
[36]. Bruno et al. demonstrated that TGF-𝛽 significantly
contributes in the induction of the angiogenic-switch of NK
cells from healthy individuals [30], promoting the induction
of the TINK/TANK CD56brightCD16−VEGFhighPlGFhighIL-
8+INF𝛾low phenotype in vitro.
A hypoxic microenvironment is another common feature
shared between the decidua and the TME [38, 39]. A
combination of TGF-𝛽 hypoxia and 5-aza-2󸀠-deoxycytidine,
a demethylating agent, has been found to convert FACS
sorted peripheral blood CD56dimCD16+NK cells into dNKs,
characterized by low cytotoxicity and high expression levels
of VEGF, the CD9 dNK marker, and KIRs [36].
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Adenosine is a soluble immunomodulatory molecule
acting through adenosine receptors expressed on diverse
immune cell type, including NK cells [40, 41]. Up to 20-
fold increases in the adenosine content in extracellular fluid
of solid carcinomas have been reported [42]. Adenosine
accumulation is partially associated with hypoxia and its
release in the extracellular environment and can impair
NK cell cytolytic activities by decreasing TNF-𝛼 secretion
(following IL-2 stimulation), decreasing cytotoxic granule
exocytosis, and attenuating perforin and Fas ligand-mediated
cytotoxic activity as far as cytokine release. Most of these
effects are attributed to stimulation of the cyclic adenosine
monophosphate/protein kinase A (PKA) pathway, following
the binding of adenosine to A2A receptors on NK cells
[43].
Recently, great interests arise on tumour released vesicles,
including exosomes, in shaping immune cell response [44,
45]. Exosomes are small (40 to 110 nm) membrane vesicles
of endocytic origin which are actively secreted from several
cell types. Exosome content includes a variety of biologically
active molecules such as proteins, mRNAs, and miRNAs
reflecting the cell of origin. They probably mediate a range
of local and systematic functions, including immune stim-
ulation or suppression, cell-to-cell communication, deliv-
ery of proteins, and genetic material, including miRNA,
tumour immune escape, and tumour cell communication
[46, 47]. Tumour derived exosomes appear to regulate NK
cells impairing their killing activity by downregulating per-
forin/granzyme production and/or NKG2D ligand expres-
sion [48, 49]. Exosome release could explain the effects of
tumours on the polarization of peripheral NK cells towards
TANK phenotype. The NKG2D/NKG2DL system plays an
important role in tumour immune surveillance [42, 48, 49].
There are convincing evidences that exosomes derived from
diverse cancer cell lines, including mesothelioma, breast, and
prostate cancer cells, express NKG2D ligands, and thereby
downregulate NKG2D expression on NK cells and CD8+ T
cells, resulting in impaired cytotoxic effector functions [48–
50]. It has also been shown that leukaemia/lymphoma T and
B cells secrete NKG2D ligand-expressing exosomes with the
ability to impair the cytotoxic potency of NK and T cells from
healthy donors [44, 45].
Recently, STAT5 has been proposed as a key regulator
in NK cells and demonstrated that STAT5 acts as a molec-
ular switch from tumour surveillance to tumour promotion
[39]. Consistent with its function as the major STAT pro-
tein downstream of IL-7, IL-2, and IL-15, Gotthardt et al.
reported STAT5 role in tumour angiogenesis showing that
Stat5Δ/ΔNcr1-iCreTg-Vav-Bcl2 mice displayed an increased
tumour growth compared with wild-type mice [51]. In addi-
tion, production of VEGF by NK cells is higher in STAT5-
deficient mice compared with wt-mice. To elucidate the role
of VEGF production in NKp46+ cells, Gotthardt and col-
leagues established VegfaΔ/ΔNcr1-iCreTg mice, characterized
by NKp46+VEGF− cells. In v-abl+ tumour, RMA-S, and A-
MuLV-induced leukaemia tumour models, they showed a
significant reduction of tumour burden and fewer CD31+
blood vessels in tumours.
3. Natural Killer Cells in Type 1 Diabetes
Type 1 diabetes (T1D), an autoimmune disease characterized
by almost complete beta cell destruction and hyperglycaemia,
accounts for only about 5–10% of all cases of diabetes,
whereas its incidence is dramatically increasing worldwide
over the last 50 years [52]. Different immune cells, such
macrophages and dendritic and T cells, have been suggested
to play crucial roles in type 1 diabetes pathogenesis [53–55].
The contribution of autoreactive T cells to the destruction of
pancreatic 𝛽 cells as a consequence of an immunologically
mediated destruction of the pancreatic tissues has been
proposed as the key pathogenicmechanisms in type 1 diabetes
[56, 57]. Nevertheless, diverse inflammatory cells, from both
innate and adaptive immunity, interact with the pancreatic
parenchyma, supporting the overall inflammatory state in
T1D. NKs cells represent the major source of IFN-𝛾, a
Th1 proinflammatory cytokine acting as a master regulator
of different immune cell response. High release of IFN-𝛾
within the pancreatic tissues inT1Dpatientsmay significantly
contribute to the excessive, uncontrolled, and unresolved
autoimmune response mediated by autoreactive T cells.
While NK cell response against autologous pancreatic islet
has been reported in vitro [58], contrasting results have been
reported in in vivo models.
Two in vivo studies correlate NK cells to diabetes pro-
gression. In the first study (Figure 3(a)), an in vivo model of
coxsackievirus B4- (CVB4-) induced diabetes was employed,
showing that NK antiviral defence, raised by beta cells in
response to IFNs, resulted in a reduced permissiveness to
infection and subsequent natural killer (NK) cell-dependent
death [59]. Another in vivo study (Figure 3(b)), using a T cell
receptor transgenic model where T1D was induced via anti-
CTLA-4 mAb treatment, revealed that higher frequency of
NK cells exited in aggressive insulitis, resulting in b-islet cell
destruction [60].
Conversely, there are several reports supporting a pro-
tective role exerted by NK cells, in NOD mice undergoing
complete Freund’s adjuvant (CFA). In this work, NOD/SCID
mice immunizedwith CFA recover its protective effects when
CD3−DX5+ NKs were adoptively transferred into animal
recipients, by downregulating autoreactive T cell response
[61] (Figure 3(c)).
Whether the murine model employed is relevant for the
NK cell behaviour detected in the context of T1D is still
debated. For example, NOD mice are characterized by an
unusual genetic composition in the genomic regions that
influence NK cell activity.
The NKG2D activatory receptor has been demonstrated
to be overexpressed inNODNKs due to the overexpression of
its Rae-1 ligand. Further, diverse NK cell inhibitory receptors
have been found to be differentially expressed in NOD mice
as compared to C57BL/6 control animals [62]. Altogether,
these genetic peculiarities may explain the low NKs activity
detected in NODmice [62, 63].
Moving to humans (Figure 3(d)), contrasting results have
been reported as well (Figure 2). Most of them documented
low number of circulating NK cells in T1D patients [64–
66] or a functional altered state [67, 68]. The major concern
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Figure 3: Natural killer cells in type1 diabetes. Several in vivo studies correlate NK cells to diabetes progression: an in vivo model of
coxsackievirus B4- (CVB4-) induced diabetes showed that NK antiviral defence resulted in a reduced permissiveness to infection and
subsequentNK cell-dependent death (a). Anti-CTLA-4mAb treatment of T cell receptor transgenicmice demonstrated that higher frequency
of NK cells induces aggressive insulitis, resulting in b-islet cell destruction (b). A protective role of NK cells was reported in NOD mice
undergoing complete Freund’s adjuvant (CFA). NOD/SCID mice immunized with CFA recover its protective effects when CD3−DX5+ NKs
are adoptively transferred into animal recipients, by downregulating autoreactive T cell response (c). In human samples, lower expression
of the NKp30 and NKp40 was detected in type 1 diabetic patients as compared with control. Type 1 diabetic patients display an increased
frequency of KIR gene haplotypes, including the activating KIR2DS3 gene, with a genetic interaction between the KIR and HLA complexes
(d).
regarding these studies is that, even if NK cells were directly
isolated from T1D patients, the detection of functional
alteration was performed by assessing NK cell cytolysis on
K562 tumour cells.
Rodacki et al. investigated the frequency and activatory
state of peripheral blood NK cells in individuals with T1D
at different stages (recent versus long-standing onset) [69,
70]. No significant difference between the activatory state,
as detected by IFN-𝛾 and perforin release, was observed
betweenNK cells derived from either recent or long-standing
T1D patients. In contrast, lower expression of the NCR
NKp30 and NKp40 was detected in NK cell isolated from
long-standing type 1 as compared with control subjects.
Further, gene expression analysis revealed that type 1 dia-
betic patients display an increased frequency of KIR gene
haplotypes, including the activating KIR2DS3 gene, with a
genetic interaction between the KIR and HLA complexes
[69, 70].
4. Natural Killer Cells in Periodontitis
Periodontitis, defined as the inflammation of the periodon-
tium involving the supporting tissues of the teeth, affects as
much as 80% of the middle-aged population; by comparison,
the prevalence of aggressive periodontitis reaches up to
1–1.5% [71].
The role of NK cells in periodontitis has been poorly
investigated; however decreasedTh cells and upregulation of
NK cells during CP have been documented [72].
The role of NKs in periodontitis represents a still debated
issue. Indeed, contrasting results have been reported by using
human specimens.While someof them showed a relationship
between NK number, phenotype, and periodontal state [73–
76], others reported no significant correlation [73, 77].
Relevant increase of CD57 NK cells has been observed by
Fujita et al. and related to periodontal diseases progression
as a consequence of an unresolved immune response within
periodontal tissues [73–76].
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Figure 4: Interaction between NK cells and the main bacterial species involved in the pathogenesis of periodontitis. Direct recognition of
Fusobacterium nucleatum through NKp46 worsts periodontal disease (A). Actinobacillus actinomycetemcomitans stimulate dendritic cells
that in turn elicit rapid gamma interferon responses by natural killer cells (B). P. gingivalis induces a rapidly increase of type 1 cytokine
production by both dendritic cells and NK cells (C). Aggregatibacter actinomycetemcomitans induces CD2-like receptor activating cytotoxic
cells (CRACC) on NK cells, via activation of dendritic cells and subsequent interleukin 12 (IL-12) signalling that results in an aggressive (D).
NK cell following F. nucleatum recognition can release TNF-𝛼 that on one hand leads to tissue damage by stimulating prostaglandin E2 release
frommonocytes and fibroblasts and secretion of metalloproteinases that degrade extracellular matrix (ECM) proteins and on the other hand
induces osteoclast differentiation and activation by increasing RANKL expression and the suppression of osteoprotegerin, a cytokine receptor
that belongs to tumour necrosis factor (TNF) receptor superfamily expression in osteoblasts, resulting in alveolar bone resorption (E).
Contrast studies conducted by Fujita et al. and Cobb et
al. revealed relatively low numbers of natural killer cells in
chronic gingivitis and periodontitis samples, as compared to
healthy subjects’ correlation [73, 77].
Conversely, in vitro studies have focused on the inter-
action between NK cells and the main bacterial species
involved in the pathogenesis of periodontitis (Figure 4), like
A. actinomycetemcomitans, P. gingivalis, and F. nucleatum
[78].
Direct recognition of Fusobacterium nucleatum, a gram-
negative anaerobe microorganism ubiquitous to the oral
cavity [79], by the NK cell natural cytotoxicity receptor
NKp46, has been reported to aggravate periodontal disease
[78] (Figure 4(A)).
Actinobacillus actinomycetemcomitans, a gram-negative
bacterium which has been associated with severe oral infec-
tions [80], has been shown to elicit rapid gamma interferon
responses by natural killer cells, via dendritic cell stimulation
[81] (Figure 4(B)). Increased type 1 cytokine production by
both dendritic cells and NK cells, following exposition to P.
gingivalis, has been described, resulting in increased P. gin-
givalis-specific IgG2 [81] (Figure 4(C)). Aggregatibacter acti-
nomycetemcomitans, a gram-negative anaerobic bacterium
strongly associated with localized aggressive periodontitis
[82], has been reported to indirectly induces CD2-like recep-
tor activating cytotoxic cells (CRACC) on NK cells, via
activation of dendritic cells and subsequent IL-12 signalling
[83]. CRACC induction was reported to be more signifi-
cantly pronounced in aggressive than chronic periodontitis
and positively correlated with periodontal disease severity,
subgingival levels of specific periodontal pathogens, and NK
cell activation in vivo [83] (Figure 4(D)).
Other relevant mechanisms driving NK cell contribution
to periodontitis involve ncr1 receptor recognition of still
unknown ligands on F. nucleatum surface. This interaction
resulted in TNF-𝛼 secretion that on one hand leads to
tissue damage by stimulating prostaglandin E2 release from
monocytes and fibroblasts, secretion of metalloproteinases
that degrade extracellular matrix (ECM) proteins, and on the
other hand induces osteoclast differentiation and activation
by increasing RANKL expression and the suppression of
osteoprotegerin, a cytokine receptor that belongs to tumour
necrosis factor (TNF) receptor superfamily expression in
osteoblasts, resulting in alveolar bone resorption [78] (Fig-
ure 4(E)).
Several conditions associated with periodontitis have
been related to alteration inNK cells cytotoxicity. A part from
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those related to bacterial infections, T2DM [67], smoking
habits [84] have been included as related conditions.
Fanconi anemia (FA), an autosomal recessive disorder
characterized by progressive pancytopenia and congenital
malformation of the skeleton [85], periodontitis, and gingivi-
tis, represents common inflammatory states in patients with
FA [85]. Natural killer (NK) cell numbers and function have
been reported to be decreased in some FA patients and this
was associated with impairment in the differentiation process
of the NK cells subsets [85, 86]. Myers et al. showed perforin
and granzyme reduced content inNKcells fromchildrenwith
FA as compared to controls [87].
Zeidel et al. reported that smokers without chronic
obstructive pulmonary disease (COPD) showed impaired
NK cytotoxic activity in peripheral blood and alteration in
systemic production of pro- and anti-inflammatory cytokines
[84].
A study performed on Papillon-Lefe`vre syndrome (PLS),
an autosomal recessive disorder that exited in aggressive
periodontitis [88], revealed NK cell anergy, as compared
to healthy subjects with impairment of NK cell cytotoxic
function [89].
5. Natural Killer Cells in Atherosclerosis
Atherosclerosis is a chronic inflammatory disease affecting
elastic and large muscular arteries that are characterized by
lesions containing cholesterol, immune cells, smooth muscle
cells, and necrotic cores. Macrophages, dendritic cells, and
T cells represent the major immune cells populations within
developing lesions, even if other immune cell components
are involved, including NK cells [90]. Indeed, NKs have been
observedwithin atherosclerotic plaques in humans as far as in
mice [91, 92] and it has been demonstrated that in advanced
atherosclerotic lesions they mostly localized in the necrotic
core adjacent tissues, deep within plaques, and in shoulder
regions [90].
It has been suggested that several cytokines and chemok-
ines within lesions may be directly involved in NK cell
recruitment towards atherosclerotic plaque. Among all,
monocyte chemoattractant protein-1 (MCP-1) [93] as well as
fractalkine (CX3CL1) has been shown as relevant cytokines
able to enhance NK cell migration and activation result-
ing in an increased IFN-𝛾 release [94]. In addition, IL-
15, IL-12, IL-18, and IFN-𝛼, which represent major NK cell
chemoattractants, have been shown to promote atherogenic
process, potentially activating NK cells, or promoting their
crosstalk with other immune cells, including DC and mono-
cytes/macrophages [95–97] (Figure 5(a)). NKs have been
shown to participate in atherosclerosis via activatory recep-
tors that recognizeMHC-Imolecules (MICAandMICB) [98]
and by releasing IFN-𝛾, a proinflammatory cytokine [99]. In
this context, it was demonstrated that oxidized low-density
lipoprotein (LDL) can promote NK/dendritic cell crosstalk
by activating the CD48-2B4 axis and inducing an increased
production of IFN-𝛾 by NKs [100] (Figure 5(a)).
To specifically confirm that NK cells infiltrate the vessel
wall and contribute to atherosclerotic promotion and lesion
development, several in vivo models have been employed.
Whitman et al. create a chimeric atherosclerosis-susceptible
LDL receptor null (ldl-r−/−) mouse model also character-
ized by the impairment of NK cell functionality through
the expression of a transgene encoding for Ly49A. They
demonstrated that, even if no difference in either serum
total cholesterol concentrations or lipoprotein cholesterol
distribution was observed between the two groups of mice,
in Ly49A transgenic group the deficiency of functional NK
cells significantly reduced the size of atherosclerosis by 70%
in cross-sectional analysis of the aortic root and by 38% in the
intimal surface of the aortic arch [92, 99] (Figure 5(b)).
Selathurai et al. demonstrated that treatments with anti-
Asialo-GM1 inApoE(−/−)mice resulted inNKcells depletion
without affecting other lymphocytes ratios, associated with
reduced atherosclerosis (Figure 5(c)).These effects have been
shown to be independent from plasma lipids. Moreover
NKs isolated from mouse spleens for adoptive transfer into
lymphocyte-deficient ApoE(−/−)Rag2(−/−)IL2rg(−/−) mice
confirmed the proatherogenic activity of NK cells. Further,
the transfer of IFN-𝛾-deficient NK cells, but not granzyme
B and perforin-deficient NK cells, resulted in an increased
lesion size in the lymphocyte-deficient ApoE(−/−) mice as in
wild-type NK cells. Necrotic core was increased by wild-type
NK cells, whereas no changes were observed with perforin-
and granzyme B-deficient NK cell transfer [98] (Figure 5(d)).
Cheng et al. showed that combined B, T, and NK
cell deficiency accelerates atherosclerosis in BALB/c mice,
demonstrating the impact of lymphocytes, includingNKs, on
lipoprotein metabolism along with the relevant contribution
of lymphocyte subsets in plaque composition in atheroscle-
rosis [101].
Recent studies have suggested that not only might the
presence of NKs be considered in atherosclerosis progres-
sion, but also more importantly their ability to influence
other immune cells should be evaluated. Several evidences
demonstrated that NKs within atherosclerotic plaque are
activated by dendritic cells. NK-released cytokines are able in
turn to promote DC maturation, leading to an exacerbation
inflammatory response.NK/DC crosstalkmight be envisaged
as a potential interaction occurring within atherosclerotic
lesions, which might worsen disease progression [102] (Fig-
ure 5(a)). In fact, the crosstalk between activated dendritic
cells/macrophages and NK cells induces IFN-𝛾 release by
NK cells that in turn promotes metalloproteinases (MMPs)
secretion from cDCs and MΦ. Activated MΦ produce TNF-
𝛼 increasing enhance endothelial cell adhesion molecules
and MMPs can damage the extracellular matrix leading to
atherosclerotic plaque destabilization [102] (Figure 5(a)).
Indirect evidence that NK cells might contribute to
atherosclerotic disease is also provided by clinical obser-
vations in atherosclerotic patients. Recently, in a cohort of
124 patients it has been demonstrated that increased NK
numbers were observed in the arm of the study including
those patients with complications, suggesting NK cell direct
contribution in atherosclerosis progression [103]. Similarly, in
elderly atherosclerotic patients, an increased number of total
circulating NKs characterized by an impaired cytotoxicity
were shown [104]. According to these evidences, a significant
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cells that in turn promotemetalloproteinases (MMPs) secretion from cDCs andMΦ (a). In a chimeric atherosclerosis-susceptible low-density
lipoprotein (LDL) receptor null (ldl-r−/−) mouse model, characterized by the impairment of NK cell functionality through the expression
of a transgene encoding for Ly49A, it has been demonstrated that even if no difference in either serum total cholesterol concentrations or
lipoprotein cholesterol distribution was observed between the two groups of mice, in Ly49A transgenic group, the deficiency of functional
NK cells significantly reduced the size of atherosclerosis by 70% in cross-sectional analysis of the aortic root and by 38% in the intimal
surface of the aortic arch (b). The administration of anti-Asialo-GM1 antibodies in ApoE(−/−) mice induces a NK cells depletion leading to
an attenuation of atherosclerosis (c). The transfer of NK cells isolated from murine spleen into ApoE(−/−)Rag2(−/−)IL2rg(−/−) induces an
enhancement of atherosclerosis (d).
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reduction of CD56dim NK cells and a concomitant loss of NK
cell function in terms of cytolytic activity were also found in
patients with unstable coronary artery disease (CAD) [105].
6. Conclusion
The contribution of natural killer cells to inflammatory
disease insurgence and progression represent an intriguing
topic for both basic scientists and clinicians. It is now
clear that immune cell plasticity within the pathological
microenvironment acts not only at local tissue but also at
systemic levels. Several studies performed in different and
distant pathologies like cancer, diabetes, and dental disorders
that share an inflammatory state as a crucial hallmark showed
altered NK cell activity at both local and systemic levels. This
will be crucial to propose NK cells as potential circulating
biomarkers to early detect diverse syndrome and/or predict
further outcome.
Some studies, here discussed, supported the evidence that
altered NK cell activities (enhanced/uncontrolled cytolysis
versus impaired cytolytic functions) are associated with
protective or deleterious effects. This knowledge suggests
that further studies, requiring proper animal models and
translation into human, are necessary to clarify the contribu-
tion of NK cells to the progression of inflammatory-related
pathologies, aiming at identifying potential modulators able
to shape NK cells, according to the pathological context.
Finally, considering their direct and indirect (crosstalk with
other arms on innate and adaptive immunity) contribution to
inflammatory conditions, NK cells can be placed as relevant
orchestrators in chronic diseases.
Abbreviations
ADCC: Antibody-dependent cellular cytotoxicity
A-MuLV: Abelson murine leukaemia virus
CD: Cluster of differentiation
CFA: Complete Freund’s adjuvant
COPD: Chronic obstructive pulmonary disease
CP: Chronic periodontitis
CRACC: CD2-like receptor activating cytotoxic
cells
CTLA: Cytotoxic T-lymphocyte antigen
CVB4: Coxsackievirus B4
CX3CL1: Fractalkine
DC: Dendritic cells
dNK: Decidual NK cell
ECM: Extracellular matrix
FA: Fanconi anemia
FACS: Fluorescence-activated cell sorting
HLA: Human leukocyte antigen
IFN: Interferon
IL: Interleukin
ITAM: Immunoreceptor tyrosine-based
activation motifs
ITIM: Immune tyrosine-based inhibitory motifs
KIR: Killer cell immunoglobulin-like receptor
LDL: Low-density lipoprotein
Ly49A: Killer cell lectin-like receptor subfamily A
M: Macrophages
MΦ: Naı¨ve macrophages
MCP-1: Monocyte chemoattractant protein-1
MDSC: Myeloid-derive-suppressor cells
MHC: Major histocompatibility complex
MICA: MHC class I polypeptide-related sequence
A
MICB: MHC class I polypeptide-related sequence
B
MMPs: Metalloproteinases
miRNA: Micro-RNA
mRNA: Messenger RNA
N: Neutrophils
NCR: Natural cytotoxicity receptors
NK: Natural killer
NKG: Natural killer group
NOD: Nonobese diabetic
NOD/SCID: Nonobese diabetic/severe combined
immunodeficiency
NSCLC: Non-small-cell lung cancer
PKA: Protein kinase A
PlGF: Placental growth factor
PLS: Papillon-Lefe`vre syndrome
Rae: Retinoic acid early inducible
RANKL: Receptor activator of nuclear factor-𝜅B
ligand
RMA-S: Rejected an MHC class I-deficient tumour
cell line
SMAD: Small mother against decapentaplegic
STAT: Signal transducers and activators of
transcription
Th: T helper
TANKs: Tumour associated natural killer cells
TINKs: Tumour infiltrating natural killer cells
TGF: Transforming growth factor
TME: Tumour microenvironment
TNF: Tumour necrosis factor
Treg: T regulatory
T1D: Type 1 diabetes
T2DM: Type 2 diabetes mellitus
v-abl: Abelson murine leukaemia viral oncogene
homolog 1
VEGF: Vascular endothelial growth factor.
Disclosure
Luca Parisi and Barbara Bassani are co-first authors and
Giampietro Farronato and Antonino Bruno are co-last
authors.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Authors’ Contributions
Luca Parisi, Barbara Bassani, Giampietro Farronato, and
Antonino Bruno share equal contribution.
10 Journal of Immunology Research
Acknowledgments
Barbara Bassani and Elisabetta Gini are students of the
Ph.D. program in Biotechnology, Biosciences, and Surgical
Technologies, School in Biological and Medical Sciences,
University of Insubria. Antonino Bruno was a FIRC (Fon-
dazione Italiana per la Ricerca sul Cancro) fellow and is
currently a fellow for Fondazione Umberto Veronesi (FUV).
References
[1] P. Libby, “Inflammation and cardiovascular disease mecha-
nisms,” The American Journal of Clinical Nutrition, vol. 83, no.
2, pp. 456S–460S, 2006.
[2] S. Amor, F. Puentes, D. Baker, and P. Van Der Valk, “Inflamma-
tion in neurodegenerative diseases,” Immunology, vol. 129, no. 2,
pp. 154–169, 2010.
[3] C.K.Glass, K. Saijo, B.Winner,M.C.Marchetto, and F.H.Gage,
“Mechanisms underlying inflammation in neurodegeneration,”
Cell, vol. 140, no. 6, pp. 918–934, 2010.
[4] T. Wyss-Coray and L. Mucke, “Inflammation in neurodegener-
ative disease—a double-edged sword,”Neuron, vol. 35, no. 3, pp.
419–432, 2002.
[5] M. Y. Donath, “Targeting inflammation in the treatment of type
2 diabetes: time to start,”Nature Reviews Drug Discovery, vol. 13,
no. 6, pp. 465–476, 2014.
[6] N. Esser, S. Legrand-Poels, J. Piette, A. J. Scheen, and N. Paquot,
“Inflammation as a link between obesity, metabolic syndrome
and type 2 diabetes,”Diabetes Research andClinical Practice, vol.
105, no. 2, pp. 141–150, 2014.
[7] K. Esposito and D. Giugliano, “The metabolic syndrome and
inflammation: association or causation?”Nutrition, Metabolism
and Cardiovascular Diseases, vol. 14, no. 5, pp. 228–232, 2004.
[8] R. Monteiro and I. Azevedo, “Chronic inflammation in obesity
and the metabolic syndrome,” Mediators of Inflammation, vol.
2010, Article ID 289645, 10 pages, 2010.
[9] F. R. Balkwill and A.Mantovani, “Cancer-related inflammation:
common themes and therapeutic opportunities,” Seminars in
Cancer Biology, vol. 22, no. 1, pp. 33–40, 2012.
[10] L. M. Coussens and Z. Werb, “Inflammation and cancer,”
Nature, vol. 420, no. 6917, pp. 860–867, 2002.
[11] C. I. Diakos, K. A. Charles, D. C. McMillan, and S. J. Clarke,
“Cancer-related inflammation and treatment effectiveness,”The
Lancet Oncology, vol. 15, no. 11, pp. e493–e503, 2014.
[12] A. Bruno, A. Pagani, L. Pulze et al., “Orchestration of angiogen-
esis by immune cells,” Frontiers in Oncology, vol. 4, article 131,
2014.
[13] A. Mantovani, M. A. Cassatella, C. Costantini, and S. Jaillon,
“Neutrophils in the activation and regulation of innate and
adaptive immunity,” Nature Reviews Immunology, vol. 11, no. 8,
pp. 519–531, 2011.
[14] A. Sica and A.Mantovani, “Macrophage plasticity and polariza-
tion: In vivo veritas,” Journal of Clinical Investigation, vol. 122,
no. 3, pp. 787–795, 2012.
[15] B. R. Blazar, W. J. Murphy, and M. Abedi, “Advances in
graft-versus-host disease biology and therapy,” Nature Reviews
Immunology, vol. 12, no. 6, pp. 443–458, 2012.
[16] L. L. Lanier, “Turning on natural killer cells,” Journal of
Experimental Medicine, vol. 191, no. 8, pp. 1259–1262, 2000.
[17] F. Gerosa, B. Baldani-Guerra, C. Nisii, V. Marchesini, G. Carra,
and G. Trinchieri, “Reciprocal activating interaction between
natural killer cells and dendritic cells,” Journal of Experimental
Medicine, vol. 195, no. 3, pp. 327–333, 2002.
[18] N. C. Fernandez, A. Lozier, C. Flament et al., “Dendritic cells
directly trigger NK cell functions: cross-talk relevant in innate
anti-tumor immune responses in vivo,” Nature Medicine, vol. 5,
no. 4, pp. 405–411, 1999.
[19] R. Mocikat, H. Braumu¨ller, A. Gumy et al., “Natural killer cells
activated by MHC class ILow targets prime dendritic cells to
induce protective CD8 T cell responses,” Immunity, vol. 19, no.
4, pp. 561–569, 2003.
[20] E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini,
“Functions of natural killer cells,” Nature Immunology, vol. 9,
no. 5, pp. 503–510, 2008.
[21] P. Le Bouteiller, “Human decidual NK cells: unique and tightly
regulated effector functions in healthy and pathogen-infected
pregnancies,” Frontiers in Immunology, vol. 4, article 404, 2013.
[22] S. M. Blois, B. F. Klapp, and G. Barrientos, “Decidualization and
angiogenesis in early pregnancy: unravelling the functions of
DC and NK cells,” Journal of Reproductive Immunology, vol. 88,
no. 2, pp. 86–92, 2011.
[23] J. Hanna, D. Goldman-Wohl, Y. Hamani et al., “Decidual NK
cells regulate key developmental processes at the human fetal-
maternal interface,” Nature Medicine, vol. 12, no. 9, pp. 1065–
1074, 2006.
[24] F. R. Balkwill, M. Capasso, and T. Hagemann, “The tumor
microenvironment at a glance,” Journal of Cell Science, vol. 125,
no. 23, pp. 5591–5596, 2012.
[25] A. Bruno, A. Pagani, E. Magnani et al., “Inflammatory angio-
genesis and the tumor microenvironment as targets for cancer
therapy and prevention,” Cancer Treatment and Research, vol.
159, pp. 401–426, 2014.
[26] S. M. Crusz and F. R. Balkwill, “Inflammation and cancer:
advances and new agents,” Nature Reviews Clinical Oncology,
vol. 12, no. 10, pp. 584–596, 2015.
[27] D. M. Noonan, A. De Lerma Barbaro, N. Vannini, L. Mor-
tara, and A. Albini, “Inflammation, inflammatory cells and
angiogenesis: decisions and indecisions,” Cancer andMetastasis
Reviews, vol. 27, no. 1, pp. 31–40, 2008.
[28] D. Hanahan and R. A.Weinberg, “Hallmarks of cancer: the next
generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
[29] A. Bruno, G. Ferlazzo, A. Albini, and D. M. Noonan, “A think
tank of TINK/TANKs: tumor-infiltrating/tumor-associated
natural killer cells in tumor progression and angiogenesis,”
Journal of the National Cancer Institute, vol. 106, no. 8, article
dju200, 2014.
[30] A. Bruno, C. Focaccetti, A. Pagani et al., “The proangiogenic
phenotype of natural killer cells in patients with non-small cell
lung cancer,” Neoplasia, vol. 15, no. 2, pp. 133–142, 2013.
[31] J. Baginska, E. Viry, J. Paggetti et al., “The critical role of
the tumor microenvironment in shaping natural killer cell-
mediated anti-tumor immunity,” Frontiers in Immunology, vol.
4, article 490, 2013.
[32] R. A. Flavell, S. Sanjabi, S. H. Wrzesinski, and P. Licona-Limo´n,
“The polarization of immune cells in the tumour environment
by TGFbeta,” Nature Reviews Immunology, vol. 10, no. 8, pp.
554–567, 2010.
[33] H. Ikushima and K. Miyazono, “TGFΒ 2 signalling: a complex
web in cancer progression,” Nature Reviews Cancer, vol. 10, no.
6, pp. 415–424, 2010.
[34] L. Yang, Y. Pang, andH. L.Moses, “TGF-𝛽 and immune cells: an
important regulatory axis in the tumor microenvironment and
Journal of Immunology Research 11
progression,” Trends in Immunology, vol. 31, no. 6, pp. 220–227,
2010.
[35] D. S. Allan, B. Rybalov, G. Awong et al., “TGF-beta affects
development and differentiation of human natural killer cell
subsets,” European Journal of Immunology, vol. 40, no. 8, pp.
2289–2295, 2010.
[36] A. S. Cerdeira, A. Rajakumar, C. M. Royle et al., “Conversion of
peripheral blood NK cells to a decidual NK-like phenotype by a
cocktail of defined factors,” Journal of Immunology, vol. 190, no.
8, pp. 3939–3948, 2013.
[37] D. B. Keskin, D. S. J. Allan, B. Rybalov et al., “TGF𝛽 promotes
conversion of CD16+ peripheral blood NK cells into CD16- NK
cells with similarities to decidual NK cells,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 104, no. 9, pp. 3378–3383, 2007.
[38] K. D. Beaman, M. K. Jaiswal, G. K. Katara et al., “Pregnancy is
a model for tumors, not transplantation,” American Journal of
Reproductive Immunology, vol. 76, no. 1, pp. 3–7, 2016.
[39] S. G. Holtan, D. J. Creedon, P. Haluska, and S. N. Markovic,
“Cancer and pregnancy: parallels in growth, invasion, and
immune modulation and implications for cancer therapeutic
agents,” Mayo Clinic Proceedings, vol. 84, no. 11, pp. 985–1000,
2009.
[40] D. W. Hoskin, J. S. Mader, S. J. Furlong, D. M. Conrad, and
J. Blay, “Inhibition of T cell and natural killer cell function by
adenosine and its contribution to immune evasion by tumor
cells (Review),” International Journal of Oncology, vol. 32, no.
3, pp. 527–535, 2008.
[41] V. Kumar and A. Sharma, “Adenosine: an endogenous mod-
ulator of innate immune system with therapeutic potential,”
European Journal of Pharmacology, vol. 616, no. 1–3, pp. 7–15,
2009.
[42] G. Berchem, M. Z. Noman, M. Bosseler et al., “Hypoxic tumor-
derived microvesicles negatively regulate NK cell function
by a mechanism involving TGF-beta and miR23a transfer,”
Oncoimmunology, vol. 5, no. 4, Article ID e1062968, 2016.
[43] L. Antonioli, C. Blandizzi, P. Pacher, and G. Hasko´, “Immunity,
inflammation and cancer: a leading role for adenosine,” Nature
Reviews Cancer, vol. 13, no. 12, pp. 842–857, 2013.
[44] D.W. Greening, S. K. Gopal, R. Xu, R. J. Simpson, andW. Chen,
“Exosomes and their roles in immune regulation and cancer,”
Seminars in Cell and Developmental Biology, vol. 40, pp. 72–81,
2015.
[45] J. Webber, V. Yeung, and A. Clayton, “Extracellular vesicles as
modulators of the cancer microenvironment,” Seminars in Cell
and Developmental Biology, vol. 40, pp. 27–34, 2015.
[46] K. Denzer, M. J. Kleijmeer, H. F. G. Heijnen, W. Stoorvogel,
and H. J. Geuze, “Exosome: from internal vesicle of the
multivesicular body to intercellular signaling device,” Journal of
Cell Science, vol. 113, no. 19, pp. 3365–3374, 2000.
[47] H. Valadi, K. Ekstro¨m, A. Bossios, M. Sjo¨strand, J. J. Lee,
and J. O. Lo¨tvall, “Exosome-mediated transfer of mRNAs and
microRNAs is a novel mechanism of genetic exchange between
cells,” Nature Cell Biology, vol. 9, no. 6, pp. 654–659, 2007.
[48] A. Clayton, J. P. Mitchell, J. Court, S. Linnane, M. D. Mason,
and Z. Tabi, “Human tumor-derived exosomes down-modulate
NKG2D expression,” Journal of Immunology, vol. 180, no. 11, pp.
7249–7258, 2008.
[49] A. Clayton and Z. Tabi, “Exosomes and the MICA-NKG2D
system in cancer,” Blood Cells, Molecules, and Diseases, vol. 34,
no. 3, pp. 206–213, 2005.
[50] L. Muller, M. Mitsuhashi, P. Simms, W. E. Gooding, and T.
L. Whiteside, “Tumor-derived exosomes regulate expression
of immune function-related genes in human T cell subsets,”
Scientific Reports, vol. 6, article 20254, 2016.
[51] D.Gotthardt, E.M. Putz, E. Grundschober et al., “STAT5 is a key
regulator in NK cells and acts as a molecular switch from tumor
surveillance to tumor promotion,” Cancer Discovery, vol. 6, no.
4, pp. 414–429, 2016.
[52] J. E. Phillips, J. J. Couper, M. A. S. Penno et al., “Type 1 diabetes:
a disease of developmental origins,” Pediatric Diabetes, 2016.
[53] J. Huang, Y. Xiao, A. Xu, and Z. Zhou, “Neutrophils in type 1
diabetes,” Journal of Diabetes Investigation, vol. 7, no. 5, pp. 652–
663, 2016.
[54] N. Van Gassen, W. Staels, E. Van Overmeire et al., “Concise
review: macrophages: versatile gatekeepers during pancreatic
beta-cell development, injury, and regeneration,” Stem Cells
Translational Medicine, vol. 4, no. 6, pp. 555–563, 2015.
[55] D. H. Wagner, “Of the multiple mechanisms leading to type
1 diabetes, T cell receptor revision may play a prominent role
(is type 1 diabetes more than a single disease?),” Clinical &
Experimental Immunology, vol. 185, no. 3, pp. 271–280, 2016.
[56] G. S. Eisenbarth, “Type I diabetes mellitus. A chronic autoim-
mune disease,”New England Journal ofMedicine, vol. 314, no. 21,
pp. 1360–1368, 1986.
[57] M. A. Kelly, M. L. Rayner, C. H. Mijovic, and A. H. Barnett,
“Molecular aspects of type 1 diabetes,”Molecular Pathology, vol.
56, no. 1, pp. 1–10, 2003.
[58] A. G. Baxter and M. J. Smyth, “The role of NK cells in
autoimmune disease,” Autoimmunity, vol. 35, no. 1, pp. 1–14,
2002.
[59] M. Flodstrom, A. Maday, D. Balakrishna, M. M. Cleary, A.
Yoshimura, and N. Sarvetnick, “Target cell defense prevents the
development of diabetes after viral infection,”Nature Immunol-
ogy, vol. 3, no. 4, pp. 373–382, 2002.
[60] L. Poirot, C. Benoist, and D. Mathis, “Natural killer cells
distinguish innocuous and destructive forms of pancreatic islet
autoimmunity,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 101, no. 21, pp. 8102–8107,
2004.
[61] I. Lee, H. Qin, J. Trudeau, J. Dutz, and R. Tan, “Regulation
of autoimmune diabetes by complete Freund's adjuvant is
mediated by NK cells,” Journal of Immunology, vol. 172, no. 2,
pp. 937–942, 2004.
[62] L. D. Poulton, M. J. Smyth, C. G. Hawke et al., “Cytometric and
functional analyses of NK and NKT cell deficiencies in NOD
mice,” International Immunology, vol. 13, no. 7, pp. 887–896,
2001.
[63] S. E. Johansson, H. Hall, J. Bjo¨rklund, and P. Ho¨glund, “Broadly
impaired NK cell function in non-obese diabetic mice is
partially restored by NK cell activation in vivo and by IL-12/IL-
18 in vitro,” International Immunology, vol. 16, no. 1, pp. 1–11,
2004.
[64] M. J. Hussain, L. Alviggi, B. A. Millward, R. D. G. Leslie, D. A.
Pyke, and D. Vergani, “Evidence that the reduced number of
natural killer cells in Type 1 (insulin-dependent) diabetes may
be genetically determined,”Diabetologia, vol. 30, no. 12, pp. 907–
911, 1987.
[65] M. P. N. Nair, E. W. Lewis, and S. A. Schwartz, “Immunoreg-
ulatory dysfunctions in type I diabetes: natural and antibody-
dependent cellular cytotoxic activities,” Journal of Clinical
Immunology, vol. 6, no. 5, pp. 363–372, 1986.
12 Journal of Immunology Research
[66] K. Negishi, N.Waldeck, G. Chandy et al., “Natural killer cell and
islet killer cell activities in Type 1 (insulin-dependent) diabetes,”
Diabetologia, vol. 29, no. 6, pp. 352–357, 1986.
[67] R. Lorini, A. Moretta, A. Valtorta et al., “Cytotoxic activity
in children with insulin-dependent diabetes mellitus,” Diabetes
Research and Clinical Practice, vol. 23, no. 1, pp. 37–42, 1994.
[68] R. G.Wilson, J. Anderson, B. K. Shenton, M. D.White, R. M. R.
Taylor, and G. Proud, “Natural killer cells in insulin dependent
diabetes mellitus,” British Medical Journal, vol. 293, no. 6541, p.
244, 1986.
[69] M. Rodacki, A. Milech, and J. E. P. D. Oliveira, “NK cells and
type 1 diabetes,” Clinical and Developmental Immunology, vol.
13, no. 2-4, pp. 101–107, 2006.
[70] M. Rodacki, B. Svoren, V. Butty et al., “Altered natural killer cells
in type 1 diabetic patients,” Diabetes, vol. 56, no. 1, pp. 177–185,
2007.
[71] G. Hajishengallis, “Periodontitis: from microbial immune sub-
version to systemic inflammation,” Nature Reviews Immunol-
ogy, vol. 15, no. 1, pp. 30–44, 2015.
[72] O. A. Gonzalez, M. J. Novak, S. Kirakodu et al., “Comparative
analysis of gingival tissue antigen presentation pathways in
ageing and periodontitis,” Journal of Clinical Periodontology,
vol. 41, no. 4, pp. 327–339, 2014.
[73] S. Fujita, H. Takahashi, H. Okabe, Y. Ozaki, Y. Hara, and I. Kato,
“Distribution of natural killer cells in periodontal diseases: an
immunohistochemical study.,” Journal of Periodontology, vol.
63, no. 8, pp. 686–689, 1992.
[74] W. Kopp, “Density and localization of lymphocytes with
natural-killer (NK) cell activity in periodontal biopsy spec-
imens from patients with severe periodontitis,” Journal of
Clinical Periodontology, vol. 15, no. 10, pp. 595–600, 1988.
[75] S. Stelin, H. Ramakrishan, A. Talwar, K. V. Arun, and T. S.
Kumar, “Immunohistological analysis of CD1a langerhans cells
and CD57 natural killer cells in healthy and diseased human
gingival tissue: a comparative study,” Journal of Indian Society
of Periodontology, vol. 13, no. 3, pp. 150–154, 2009.
[76] S. E.Wynne, L. J.Walsh, G. J. Seymour, andR.N. Powell, “In situ
demonstration of natural killer (NK) cells in human gingival
tissue.,” Journal of Periodontology, vol. 57, no. 11, pp. 699–702,
1986.
[77] C.M. Cobb, O. Singla, P. H. Feil, F. C.Theisen, and R. E. Schultz,
“Comparison of NK-cell (Leu-7+ and Leu-11b+) populations in
clinically healthy gingiva, chronic gingivitis and chronic adult
periodontitis,” Journal of Periodontal Research, vol. 24, no. 1, pp.
1–7, 1989.
[78] S. Chaushu, A. Wilensky, C. Gur et al., “Direct recognition
of fusobacterium nucleatum by the NK cell natural cytotox-
icity receptor NKp46 aggravates periodontal disease,” PLoS
Pathogens, vol. 8, no. 3, Article ID e1002601, 2012.
[79] Y. W. Han, R. W. Redline, M. Li, L. Yin, G. B. Hill, and T.
S. McCormick, “Fusobacterium nucleatum Induces Premature
and Term Stillbirths in Pregnant Mice: implication of oral
bacteria in preterm birth,” Infection and Immunity, vol. 72, no.
4, pp. 2272–2279, 2004.
[80] J. Slots, H. S. Reynolds, and R. J. Genco, “Actinobacillus acti-
nomycetemcomitans in human periodontal disease: a cross-
sectional microbiological investigation,” Infection and Immu-
nity, vol. 29, no. 3, pp. 1013–1020, 1980.
[81] T. Kikuchi, C. L. Hahn, S. Tanaka, S. E. Barbour, H. A.
Schenkein, and J. G. Tew, “Dendritic cells stimulated with Acti-
nobacillus actinomycetemcomitans elicit rapid gamma inter-
feron responses by natural killer cells,” Infection and Immunity,
vol. 72, no. 9, pp. 5089–5096, 2004.
[82] S. S. Socransky and A. D. Haffajee, “The bacterial etiology of
destructive periodontal disease: current concepts,” Journal of
Periodontology, vol. 63, no. 4, pp. 322–331, 1992.
[83] B. Kramer, M. Kebschull, M. Nowak et al., “Role of the NK
cell-activating receptor CRACC in periodontitis,” Infection and
Immunity, vol. 81, no. 3, pp. 690–696, 2013.
[84] A. Zeidel, B. Beilin, I. Yardeni, E. Mayburd, G. Smirnov, and
H. Bessler, “Immune response in asymptomatic smokers,” Acta
Anaesthesiologica Scandinavica, vol. 46, no. 8, pp. 959–964,
2002.
[85] A. Acikgoz, F. O. Ozden, T. Fisgin et al., “Oral and dental find-
ings in Fanconi’s anemia,” Pediatric Hematology and Oncology,
vol. 22, no. 6, pp. 531–539, 2005.
[86] G. A. Justo, M. A. Bitencourt, R. Pasquini et al., “Immune status
of Fanconi anemia patients: decrease in T CD8 and CD56 dim
CD16+ NK lymphocytes,” Annals of Hematology, vol. 93, no. 5,
pp. 761–767, 2014.
[87] K. C.Myers, J. J. Bleesing, S.M.Davies et al., “Impaired immune
function in children with Fanconi anaemia,” British Journal of
Haematology, vol. 154, no. 2, pp. 234–240, 2011.
[88] V. J. Rathod and N. V. Joshi, “Papillon-Lefevre syndrome: a
report of two cases,” Journal of Indian Society of Periodontology,
vol. 14, no. 4, pp. 275–278, 2010.
[89] T. Lundgren, R. S. Parhar, S. Renvert, and D. N. Tatakis,
“Impaired cytotoxicity in Papillon-Lefe`vre syndrome,” Journal
of Dental Research, vol. 84, no. 5, pp. 414–417, 2005.
[90] Y. Li, K. To, P. Kanellakis et al., “CD4+ natural killer T cells
potently augment aortic root atherosclerosis by perforin-and
granzyme b-dependent cytotoxicity,” Circulation Research, vol.
116, no. 2, pp. 245–254, 2015.
[91] Y. V. Bobryshev and R. S. A. Lord, “Identification of natural
killer cells in human atherosclerotic plaque,”Atherosclerosis, vol.
180, no. 2, pp. 423–427, 2005.
[92] S. C.Whitman, D. L. Rateri, S. J. Szilvassy,W. Yokoyama, and A.
Daugherty, “Depletion of natural killer cell function decreases
atherosclerosis in low-density lipoprotein receptor null mice,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no.
6, pp. 1049–1054, 2004.
[93] P. Allavena, G. Bianchi, D. Zhou et al., “Induction of natural
killer cell migration by monocyte chemotactic protein−1, −2
and −3,” European Journal of Immunology, vol. 24, no. 12, pp.
3233–3236, 1994.
[94] H. Umehara, E. T. Bloom, T. Okazaki, Y. Nagano, O. Yoshie, and
T. Imai, “Fractalkine in vascular biology: from basic research
to clinical disease,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 24, no. 1, pp. 34–40, 2004.
[95] D. A. Chistiakov, I. A. Sobenin, A. N. Orekhov, and Y. V.
Bobryshev, “Dendritic cells in atherosclerotic inflammation: the
complexity of functions and the peculiarities of pathophysio-
logical effects,” Frontiers in Physiology, vol. 5, article 00196, 2014.
[96] Z. Mallat, A. Corbaz, A. Scoazec et al., “Interleukin-
18/interleukin-18 binding protein signaling modulates
atherosclerotic lesion development and stability.,” Circulation
research, vol. 89, no. 7, pp. E41–E45, 2001.
[97] K. Uyemura, L. L. Demer, S. C. Castle et al., “Cross-regulatory
roles of interleukin (IL)-12 and IL-10 in atherosclerosis,” Journal
of Clinical Investigation, vol. 97, no. 9, pp. 2130–2138, 1996.
Journal of Immunology Research 13
[98] A. Selathurai, V. Deswaerte, P. Kanellakis et al., “Natural killer
(NK) cells augment atherosclerosis by cytotoxic-dependent
mechanisms,” Cardiovascular Research, vol. 102, no. 1, pp. 128–
137, 2014.
[99] M. F. Linton, A. S. Major, and S. Fazio, “Proatherogenic role
forNKcells revealed,”Arteriosclerosis,Thrombosis, andVascular
Biology, vol. 24, no. 6, pp. 992–994, 2004.
[100] K. Dong, J. Ge, S. Gu et al., “Ox-LDL can enhance the
interaction of mice natural killer cells and dendritic cells via the
CD48-2B4 pathway,” Heart and Vessels, vol. 26, no. 6, pp. 637–
645, 2011.
[101] F. Cheng, L. Twardowski, K. Reifenberg et al., “Combined B,
T and NK cell deficiency accelerates atherosclerosis in BALB/c
mice,” PLoS One, vol. 11, no. 8, Article ID e0157311, 2016.
[102] I. Bonaccorsi, C. De Pasquale, S. Campana et al., “Natural
killer cells in the innate immunity network of atherosclerosis,”
Immunology Letters, vol. 168, no. 1, pp. 51–57, 2015.
[103] K. Kotfis, J. Biernawska, M. Zegan-Baranska, andM. Zukowski,
“Peripheral Blood Lymphocyte Subsets (CD4+, CD8+ T Cells,
NK Cells) in Patients with Cardiovascular and Neurological
Complications after Carotid Endarterectomy,” International
Journal of Molecular Sciences, vol. 16, no. 5, pp. 10077–10094,
2015.
[104] H. Bruunsgaard, A. N. Pedersen, M. Schroll, P. Skinhoj, and B.
K. Pedersen, “Decreased natural killer cell activity is associated
with atherosclerosis in elderly humans,” Experimental Gerontol-
ogy, vol. 37, no. 1, pp. 127–136, 2001.
[105] L. Jonasson, K. Backteman, and J. Ernerudh, “Loss of natural
killer cell activity in patients with coronary artery disease,”
Atherosclerosis, vol. 183, no. 2, pp. 316–321, 2005.
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
